Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 4Leukemia 4Lymphoma, Mantle-Cell 3Waldenstrom Macroglobulinemia 2Sarcoma 2Medulloblastoma 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Central Nervous System Neoplasms 2Sezary Syndrome 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Osteosarcoma 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Familial ependymoma 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 85Rituximab 80Peripheral Blood Stem Cell Transplantation 60fludarabine phosphate 58Filgrastim 40Mycophenolic Acid 37Whole-Body Irradiation 35Cyclosporine 35Radiotherapy 33Etoposide 33Busulfan 33Tacrolimus 31Antilymphocyte Serum 28Melphalan 26Methotrexate 22Prednisone 19Bortezomib 19Methylprednisolone 16Cytarabine 16Vincristine 15Lenalidomide 15Flow Cytometry 14Cord Blood Stem Cell Transplantation 13sargramostim 12Doxorubicin 12Bendamustine Hydrochloride 12fludarabine 11Dexamethasone 11Carmustine 11Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell, Marginal Zone × Gene Rearrangement × Clear all
NCT00546377 2016-05-12

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
50 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00621452 2014-08-06

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡